We are live on
!
Find out more
OCM
Orser Capital Management Portfolio holdings
AUM
$202M
1-Year Est. Return
32.65%
This Fund
S&P 500
This Quarter
Est. Return
+12.65%
1 Year Est. Return
+32.65%
3 Year Est. Return
+122.2%
5 Year Est. Return
+162.36%
10 Year Est. Return
–
AUM
$158M
AUM Growth
+$31.3M
(+25%)
Cap. Flow
+$18.1M
Cap. Flow
% of AUM
11.44%
Top 10 Holdings %
Top 10 Hldgs %
33.34%
Holding
92
New
23
Increased
39
Reduced
12
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$3.97M |
| 2 |
Zebra Technologies
ZBRA
|
+$2.15M |
| 3 |
Medtronic
MDT
|
+$1.93M |
| 4 |
ProShares Short S&P500
SH
|
+$1.68M |
| 5 |
Pfizer
PFE
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$5.38M |
| 2 |
Baxter International
BAX
|
+$2.43M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$1.67M |
| 4 |
ProShares Short QQQ
PSQ
|
+$1.46M |
| 5 |
Clorox
CLX
|
+$1.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.25% |
| 2 | Miscellaneous | 21.07% |
| 3 | Healthcare | 17.04% |
| 4 | Consumer Staples | 10.73% |
| 5 | Financials | 7.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Bristol-Myers Squibb
BMY
$130B
| $300K | 0.19% |
4,830
| – | – |
|
77
Johnson & Johnson
JNJ
$644B
| $295K | 0.19% |
1,875
| – | – |
|
78
Texas Instruments
TXN
$241B
| $295K | 0.19% |
1,800
| – | – |
|
79
Sherwin-Williams
SHW
$78.5B
| $294K | 0.19% |
+1,200
| New | +$285K |
|
80
Invesco NASDAQ Next Gen 100 ETF
QQQJ
$1.17B
| $288K | 0.18% |
+9,320
| New | +$264K |
|
81
L3Harris
LHX
$46.5B
| $280K | 0.18% |
+1,480
| New | +$271K |
|
82
Fidelity Momentum Factor ETF
FDMO
$887M
| $279K | 0.18% |
6,305
| – | – |
|
83
Coca-Cola
KO
$382B
| $268K | 0.17% |
4,885
+446
| +10% | +$23.1K |
|
84
Vanguard Dividend Appreciation ETF
VIG
$111B
| $217K | 0.14% |
1,540
-75
| -5% | -$10.2K |
|
85
Workday
WDAY
$46B
| $216K | 0.14% |
+900
| New | +$202K |
|
86
O'Reilly Automotive
ORLY
$68.9B
| $213K | 0.14% |
+7,050
| New | +$213K |
|
87
CRISPR Therapeutics
CRSP
$5.01B
| $208K | 0.13% |
+1,360
| New | +$161K |
|
88
JB Hunt Transport Services
JBHT
$25.6B
| $205K | 0.13% |
+1,500
| New | +$199K |
|
|
89
ProShares Short QQQ
PSQ
$777M
| $202K | 0.13% |
2,803
-18,760
| -87% | -$1.46M |
|
|
90
Baxter International
BAX
$12.3B
| – | – |
-30,165
| Closed | -$2.43M |
|
91
VanEck Gold Miners ETF
GDX
$28.3B
| – | – |
-18,590
| Closed | -$728K |
|
|
92
Regeneron Pharmaceuticals
REGN
$79.7B
| – | – |
-2,990
| Closed | -$1.67M |
|
Similar funds
HIA
AF
SC
SCM
NIMC
WLG
IIM
MWP
Orser Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Orser Capital Management held 92 positions worth $158M, up 25% from $127M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Orser Capital Management deployed $18.1M of net new capital in Q4 2020, opening 23 new positions and adding to 39 existing holdings. Its largest new stake was Edwards Lifesciences: 47,875 shares worth $4.37M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was Vanguard Short-Term Treasury ETF, an estimated $5.38M trimmed.
- Orser Capital Management's largest Q4 2020 buy was Edwards Lifesciences: 47,875 shares worth $4.37M.
- Orser Capital Management added most to ProShares Short S&P500 in Q4 2020, an estimated $1.68M increase.
- Orser Capital Management's biggest Q4 2020 reduction was Vanguard Short-Term Treasury ETF, cutting an estimated $5.38M.
- Orser Capital Management fully exited Baxter International in Q4 2020, selling an estimated $2.43M.
- Orser Capital Management's ten largest holdings make up 33% of its $158M portfolio in Q4 2020.
- Orser Capital Management opened 23 new positions and closed 3 in Q4 2020.
- Orser Capital Management's portfolio value rose 25% quarter-over-quarter to $158M.
Based on Orser Capital Management's 13F filing for Q4 2020, filed 2 Feb 2021.